Literature DB >> 2060572

Atropine and verapamil interactions in healthy volunteers.

E C Meyer1, D K Sommers, J C Avenant.   

Abstract

The calcium antagonist falipamil, a chemical congener of verapamil, has anticholinergic properties. It was decided to study the interaction of verapamil with the anticholinergic drugs, atropine and pirenzepine, using healthy male volunteers. After atropine alone a significant tachycardia developed at 2 min and remained significant up to 90 min. Verapamil pretreatment followed by atropine administration resulted in a significantly greater tachycardia. Pirenzepine alone caused a bradycardic response which was accentuated after verapamil pretreatment. It is postulated that short term verapamil administration is accompanied by reflex activation of the sympathetic nervous system which does not manifest with a tachycardia owing to combined influence of verapamil and vagus on the sino-atrial node. Reduction of vagal tone with atropine treatment results in sympathetic overriding of the sino-atrial suppression, thus causing an additive tachycardia. The clinical use of atropine for prolonged verapamil-induced atrio-ventricular conduction is supported by these results.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060572     DOI: 10.1007/bf00315218

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Effect of chronic verapamil therapy on cardiac norepinephrine and beta-adrenoceptor density.

Authors:  W G Nayler; J S Dillon; W J Sturrock; D J Buckley
Journal:  J Cardiovasc Pharmacol       Date:  1988-12       Impact factor: 3.105

2.  Calcium antagonists and the heart.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-10

3.  Cardiovascular actions of 5,6-dimethoxy-2-(3-[(alpha-(3,4-dimethoxy) phenylethyl)-methylamino] propyl) phthalimidine (AQ-A 39), a specific bradycardic agent.

Authors:  J Dämmgen; R Kadatz; W Diederen
Journal:  Arzneimittelforschung       Date:  1981

Review 4.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

5.  Effects of pirenzepine and atropine on gastric secretory and plasma hormonal responses to sham-feeding in patients with duodenal ulcer.

Authors:  S J Konturek; W Obtulowicz; N Kwiecień; M Dobrzańska; J Swierczek; B Kopp; J Olesky
Journal:  Scand J Gastroenterol Suppl       Date:  1980
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.